Pharmascience Launches (Pr)pms-TRANDOLAPRIL

Pharmascience has launched in Canada Prpms-TRANDOLAPRIL (angiotensin-converting enzyme inhibitor), indicated for the treatment of mild to moderate essential hypertension and the treatment following acute myocardial infarction.

"The launch of Prpms-TRANDOLAPRIL allows us to be the first generic bioequivalent to PrMAVIK available on the Canadian market." said Jean-Guy Goulet, Chief Operating Officer at Pharmascience.

In the case of mild to moderate essential hypertension, Prpms-TRANDOLAPRIL can be used alone or in association with thiazide diuretics. It can also be used for the treatment following acute myocardial infarction in clinically stable patients who have a left ventricular dysfunction, whether they do or do not have heart failure symptoms, to improve survival and reduce hospitalizations for heart failure.

High blood pressure significantly increases the risk of stroke, ischemic heart disease, peripheral vascular disease and heart failure. About 7.5 million Canadians live with this condition.

"The launch of this product demonstrates the great agility of our teams, who are dedicated to offering Canadian patients quality and lower cost treatments." Goulet said.

--------------------------------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.Cn, 

welcome to send your CV and sample works to us, 

Email: Julia.Zhang@ubmsinoexpo.com.